Pre-made Farletuzumab benchmark antibody ( Whole mAb, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/¦Ê which is being investigated for the treatment of ovarian cancer.
| Products Name (INN Index) | Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody |
|---|---|
| INN Name | Farletuzumab |
| Target | FOLR1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Ludwig Institute for Cancer Research,Morphotek,Eisai Co Ltd |
| Conditions Approved | NA |
| Conditions Active | Ovarian cancer,Non-small cell lung cancer |
| Conditions Discontinued | Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FOLR1 |
| Package |
